Sridharan Umapathy1, Radha K Dhiman1, Sandeep Grover2, Ajay Duseja1, Yogesh K Chawla1. 1. Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 2. Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Abstract
OBJECTIVES: Hepatic encephalopathy (HE) represents a spectrum of neurocognitive impairment seen in cirrhotic patients and is considered to be fully reversible with treatment; however, recent evidence suggests otherwise. This longitudinal study was carried out to evaluate the persistence of cognitive impairment in cirrhotics with prior overt HE (OHE) episode despite treatment. METHODS: Of the 213 patients screened, 107 patients who met the eligibility criteria were enrolled and 102 patients completed the study (52 patients without prior OHE episode and 50 patients with prior OHE). All patients underwent psychometric hepatic encephalopathy score (PHES) evaluation at three separate visits (day 1, day 3, and between 30 and 60 days). A one-point improvement in PHES between the first and second evaluation was considered as a measure of learning. RESULTS: Patients with a previous OHE episode showed learning impairment in PHES on repetition on day 3 (P=0.084), whereas patients without a previous OHE episode demonstrated learning effect (P<0.0001) irrespective of whether they had minimal HE (MHE) or not. Univariate analysis demonstrated that Child-Turcotte-Pugh score, lactulose and/or rifaximin therapy, the presence of MHE, and a previous OHE episode were associated with learning impairment. Multivariate analysis demonstrated that only the presence of a previous episode of OHE (adjusted odds ratio 38.398; 95% confidence interval 9.192-160.4; P<0.0001) significantly affected learning. CONCLUSIONS: This study conclusively demonstrated learning impairment in cirrhotic patients with a previous episode of OHE despite normal mental status. Improvement in PHES on repetition may be a measure of learning.
OBJECTIVES: Hepatic encephalopathy (HE) represents a spectrum of neurocognitive impairment seen in cirrhotic patients and is considered to be fully reversible with treatment; however, recent evidence suggests otherwise. This longitudinal study was carried out to evaluate the persistence of cognitive impairment in cirrhotics with prior overt HE (OHE) episode despite treatment. METHODS: Of the 213 patients screened, 107 patients who met the eligibility criteria were enrolled and 102 patients completed the study (52 patients without prior OHE episode and 50 patients with prior OHE). All patients underwent psychometric hepatic encephalopathy score (PHES) evaluation at three separate visits (day 1, day 3, and between 30 and 60 days). A one-point improvement in PHES between the first and second evaluation was considered as a measure of learning. RESULTS:Patients with a previous OHE episode showed learning impairment in PHES on repetition on day 3 (P=0.084), whereas patients without a previous OHE episode demonstrated learning effect (P<0.0001) irrespective of whether they had minimal HE (MHE) or not. Univariate analysis demonstrated that Child-Turcotte-Pugh score, lactulose and/or rifaximin therapy, the presence of MHE, and a previous OHE episode were associated with learning impairment. Multivariate analysis demonstrated that only the presence of a previous episode of OHE (adjusted odds ratio 38.398; 95% confidence interval 9.192-160.4; P<0.0001) significantly affected learning. CONCLUSIONS: This study conclusively demonstrated learning impairment in cirrhoticpatients with a previous episode of OHE despite normal mental status. Improvement in PHES on repetition may be a measure of learning.
Authors: Silvia Nardelli; Sanath Allampati; Oliviero Riggio; Kevin D Mullen; Ravi Prakash; Stefania Gioia; Ariel Unser; Melanie B White; Andrew C Fagan; James B Wade; Alessio Farcomeni; Edith A Gavis; Jasmohan S Bajaj Journal: Dig Dis Sci Date: 2016-12-30 Impact factor: 3.199
Authors: Jasmohan S Bajaj; Melanie B White; Ariel B Unser; Dinesh Ganapathy; Andrew Fagan; Edith A Gavis; Richard K Sterling; Douglas M Heuman; Scott Matherly; Puneet Puri; Arun J Sanyal; Velimir Luketic; Michael Fuchs; Muhammad S Siddiqui; R Todd Stravitz; Binu John; Leroy R Thacker; James B Wade Journal: Metab Brain Dis Date: 2016-06-25 Impact factor: 3.584
Authors: Vishwadeep Ahluwalia; James B Wade; Melanie B White; HoChong S Gilles; Douglas M Heuman; Michael Fuchs; Edith A Gavis; Andrew Fagan; Felicia Tinsley; Dinesh Ganapathy; Leroy R Thacker; Richard K Sterling; R Todd Stravitz; Puneet Puri; Arun J Sanyal; Muhammad S Siddiqui; Scott Matherly; Velimir Luketic; Joel Steinberg; F Gerard Moeller; Jasmohan S Bajaj Journal: Liver Transpl Date: 2016-10 Impact factor: 5.799
Authors: Henning Pflugrad; Anita B Tryc; Annemarie Goldbecker; Christian P Strassburg; Hannelore Barg-Hock; Jürgen Klempnauer; Karin Weissenborn Journal: World J Hepatol Date: 2017-04-08
Authors: Santosh K Yadav; Rakesh K Gupta; Vivek A Saraswat; Murali Rangan; Michael A Thomas; Sergio Rutella; Silvio Danese; Ena Wang; Francesco M Marincola; Mohammad Haris Journal: J Transl Med Date: 2015-10-06 Impact factor: 5.531